Programmable, Multispecific DNA-Origami-Based T-Cell Engagers May Prove Useful in Treating Cancer; Origami Structure Allows Attachment of Four Antibodies: Two Anti-Cancer and Two T-Cell Activators

Immunotherapy is viewed as an exceptionally promising weapon in the fight against cancer. In essence, the aim is to activate the body’s immune system in such a way that it identifies and destroys malignant cells. However, the destruction must be as effective and specific as possible, to avoid damaging healthy cells. A team of researchers from Ludwig Maximilian University (LMU), the Technical University of Munich (TUM), and Helmholtz Munich have now published a new study in Nature Nanotechnology in which they present a promising method for developing user-defined agents that can do precisely that. “The centerpiece is a tiny chassis of folded DNA strands that can be specifically fitted with any antibodies,” explains Professor Sebastian Kobold, one of the main authors. At Munich University Hospital, his team has investigated the impact of the new substrates both in vitro and in vivo. The open-access article is titled “Programmable Multispecific DNA-Origami-Based T-Cell Engagers.”